Can I Take Vitamin B12 with Fosamax (Alendronate)?

The Short Answer: No Clinically Significant Interaction

Vitamin B12 and alendronate do not share a mechanism that would produce a drug-supplement interaction. Alendronate is a nitrogen-containing bisphosphonate that suppresses bone resorption by inhibiting osteoclast activity. Vitamin B12 is a water-soluble cofactor required for one-carbon metabolism and myelin maintenance. Their paths simply do not cross in any way that modifies absorption, distribution, metabolism, or excretion of either compound.

"no direct interaction" is not the same as "take both however you like." Alendronate has strict administration requirements that apply to every co-ingested substance, including supplements. Getting those rules right is the real clinical task.

How Alendronate Is Absorbed

Oral bioavailability of alendronate is already low, roughly 0.6 to 0.7% under fasting conditions, according to the FDA-approved prescribing information for Fosamax. Any food, beverage other than plain water, or medication taken within 30 minutes of the dose reduces that absorption further by up to 60% [1]. Calcium supplements, antacids, and iron are the most studied offenders, but the principle extends to any orally ingested substance taken simultaneously.

Vitamin B12 tablets or capsules taken at the same time as alendronate could theoretically reduce alendronate absorption through the general "food effect" if they are taken together with a meal. The solution is straightforward: take alendronate first, on an empty stomach, with 6 to 8 ounces of plain water, then wait the full 30 minutes before taking B12 or any other supplement.

How Vitamin B12 Is Absorbed

B12 absorption follows a different route entirely. Dietary B12 binds to intrinsic factor secreted by gastric parietal cells, and the resulting complex is absorbed in the terminal ileum via cubilin receptors [2]. At pharmacological doses above roughly 1,000 mcg, passive diffusion across the intestinal wall also contributes, which is why high-dose oral B12 can correct deficiency even in patients with pernicious anemia [3].

Neither of these absorption mechanisms intersects with alendronate's skeletal uptake pathway. Alendronate is taken up directly into bone mineral matrix; it does not circulate through enterohepatic recycling or compete with B12 at any transporter.

Why the Metformin-B12 Link Matters for Fosamax Patients

This is where clinical nuance is required. Many patients prescribed alendronate for osteoporosis are older adults who also carry a diagnosis of type 2 diabetes. A significant proportion of those patients take metformin.

Metformin depletes vitamin B12 through a separate, well-characterized mechanism: it competitively inhibits the calcium-dependent uptake of the intrinsic factor-B12 complex at the ileal cubilin receptor [4]. The UKPDS-derived cohort data and a 2010 cross-sectional study published in BMJ Open (N=155) found that 30% of long-term metformin users had serum B12 below 150 pmol/L [5]. That depletion leads to peripheral neuropathy that can be misattributed to diabetic neuropathy, delaying treatment.

In this scenario, alendronate itself is not the cause of B12 depletion. Metformin is. The clinical relevance for a Fosamax patient is that co-prescribing metformin and alendronate creates a population that should be actively screened for B12 deficiency, not because the two drugs interact, but because both are common in the same demographic and one of them depletes B12 silently.

Proton-Pump Inhibitors Add a Second Depletion Vector

Proton-pump inhibitors (PPIs) are another common co-prescription in bisphosphonate patients. Clinicians sometimes prescribe PPIs to reduce gastrointestinal side effects from alendronate, though the FDA label for Fosamax does not list PPIs as a required co-therapy. PPIs reduce gastric acid, which impairs the peptic release of protein-bound dietary B12, reducing absorption by an estimated 10 to 65% depending on dose and duration [6]. Long-term PPI use for more than 24 months was associated with B12 deficiency in a 2013 JAMA case-control study (N=25,956 cases), with an odds ratio of 1.65 (95% CI 1.58 to 1.73) [7].

A patient on alendronate plus a PPI plus metformin carries three simultaneous B12 depletion pressures. None of them involve a direct alendronate-B12 interaction, but the composite clinical picture demands B12 monitoring.

Atrophic Gastritis in Older Adults

Atrophic gastritis, which reduces intrinsic factor secretion, affects approximately 10 to 30% of adults over age 60 [8]. Because the demographic most likely to be prescribed alendronate overlaps substantially with the demographic most likely to have atrophic gastritis, B12 deficiency can develop quietly over months to years. Serum B12 levels below 200 pg/mL warrant further investigation, and levels below 150 pg/mL are associated with neurological symptoms including subacute combined degeneration of the spinal cord [2].

Alendronate's Actual Side-Effect Profile: What B12 Does Not Change

Understanding what vitamin B12 does not affect helps set appropriate expectations.

Gastrointestinal Effects

Alendronate causes esophageal irritation, esophagitis, and esophageal ulcers in a minority of patients. The risk is reduced by maintaining upright posture for at least 30 minutes after dosing. Vitamin B12 supplementation does not reduce or worsen this risk. B12 has no relevant effect on esophageal mucosa at supplementation doses.

Upper GI intolerance affects approximately 10 to 30% of patients on oral bisphosphonates, based on pooled data across the Fracture Intervention Trial (FIT) program [9]. If a patient develops GI symptoms, B12 is not the explanation and stopping B12 will not resolve them.

Osteonecrosis of the Jaw and Atypical Femoral Fracture

These rare but serious adverse events associated with long-term bisphosphonate use are driven by excessive suppression of bone turnover, not by B12 status. B12 has no documented effect on osteoclast suppression depth or duration [10].

Hypocalcemia

Alendronate can lower serum calcium, particularly in patients with pre-existing vitamin D deficiency. Vitamin B12 does not affect calcium homeostasis. Patients taking alendronate should maintain adequate calcium and vitamin D intake per the National Osteoporosis Foundation's Clinician's Guide, which recommends 1,000 to 1,200 mg/day of elemental calcium and 800 to 1,000 IU/day of vitamin D3 for patients on bisphosphonates [11].

Does Vitamin B12 Affect Bone Health Independently?

This question goes beyond the interaction question but is worth covering because many patients taking Fosamax for osteoporosis also want to know whether B12 supplements add bone benefit.

The Homocysteine Connection

B12 deficiency raises plasma homocysteine by impairing the remethylation of homocysteine to methionine. Elevated homocysteine has been associated with increased fracture risk in observational data. A meta-analysis published in the Journal of Bone and Mineral Research (14 studies, N=9,883) found that hyperhomocysteinemia was associated with a 4-fold increase in fracture risk in older adults [12].

The proposed mechanism is that homocysteine interferes with collagen cross-linking in bone matrix. Whether correcting B12 deficiency and reducing homocysteine translates into measurable fracture reduction remains uncertain. The evidence is associational rather than from randomized controlled trials designed for fracture endpoints.

B12 Deficiency and Gait/Fall Risk

B12 deficiency causes posterior column dysfunction that impairs proprioception and gait stability. Falls are the proximate cause of most fragility fractures. A patient with untreated B12 deficiency taking alendronate may be chemically protected against bone resorption but remain at elevated fall risk due to neurological impairment. This is a practical reason to identify and treat B12 deficiency in osteoporosis patients regardless of the absence of a direct drug interaction.

Clinical Decision Framework: When to Check B12 in Alendronate Patients

The following approach, synthesized from American Gastroenterological Association (AGA) 2022 guidance [13] and clinical practice data, can guide B12 monitoring decisions in patients taking alendronate:

Step 1, Screen for co-occurring depletion risks at the time alendronate is prescribed: Ask whether the patient also takes metformin (any dose for more than 4 months), a PPI (any dose for more than 12 months), H2-receptor antagonists for more than 24 months, or has a documented history of atrophic gastritis, pernicious anemia, or prior bariatric surgery.

Step 2, Order serum B12 if any risk factor is present: The AGA 2022 clinical practice update recommends checking serum B12 in patients on long-term metformin. A baseline level should be obtained before starting metformin and rechecked every 1 to 2 years. Extend this logic to patients already on metformin when alendronate is added.

Step 3, Interpret carefully: Serum B12 has a coefficient of variation of about 10 to 25% and can appear falsely normal in patients with functional deficiency. If serum B12 is borderline (150 to 300 pg/mL) and symptoms suggest deficiency (fatigue, paresthesias, ataxia), check methylmalonic acid and total homocysteine. Elevated methylmalonic acid is the more sensitive marker of functional B12 deficiency [2].

Step 4, Replace if deficient: Oral cyanocobalamin 1,000 to 2,000 mcg daily corrects most cases, including those caused by metformin-related malabsorption, because high-dose passive diffusion bypasses the intrinsic factor step [3]. Sublingual and intramuscular formulations are alternatives for patients with pernicious anemia or post-gastrectomy states where passive diffusion is also impaired.

Step 5, Timing relative to alendronate: Take alendronate on an empty stomach with plain water, remain upright for 30 minutes, then take B12 and other supplements with breakfast or as preferred. Do not take B12 within the 30-minute window.

What the Guidelines Say About Alendronate Administration

The FDA prescribing information for Fosamax 70 mg weekly (the most commonly prescribed regimen) states: "Instruct patients to take Fosamax upon arising for the day, with a full glass (6 to 8 oz) of plain water only. Patients should not take Fosamax with mineral water, coffee, tea, juice, or other beverages" [1].

The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines on the diagnosis and treatment of postmenopausal osteoporosis reinforce this: "Patients should be instructed on proper administration of oral bisphosphonates to maximize bioavailability and minimize adverse gastrointestinal effects" [14]. Vitamin B12 is not mentioned as an exception or special case in these guidelines, consistent with its absence from any documented interaction.

Practical Supplement Schedule for Patients on Fosamax

The timing rules for alendronate affect every supplement, not just B12. Below is a practical sequence for a patient taking alendronate 70 mg weekly:

On the day of the alendronate dose:

• Wake up. Take alendronate with 6 to 8 oz of plain water. Stay upright.
• Wait a full 30 minutes. Do not eat, drink anything other than water, or take any other medication or supplement.
• After 30 minutes, take breakfast, followed by calcium (if calcium carbonate, take with food), vitamin D3, and vitamin B12.

On all other days, there are no restrictions on when B12, calcium, or vitamin D can be taken. Many patients find it easiest to maintain a consistent morning routine every day regardless.

One practical caveat: calcium supplements above 500 mg per dose reduce the absorption of many co-ingested compounds. B12 and calcium are not known to interact, but staggering large-dose calcium from other supplements by 1 to 2 hours is a reasonable general practice supported by calcium pharmacokinetics data [11].

Monitoring Summary

Patients on alendronate do not require B12 monitoring solely because of the bisphosphonate. Monitoring is indicated when additional depletion risks are present. A serum B12 level below 200 pg/mL in the presence of neurological symptoms requires prompt evaluation and treatment. Methylmalonic acid is the preferred confirmatory test when serum B12 is borderline.

The 2022 AGA guidance specifies annual B12 testing for all patients on long-term metformin [13]. Any patient who takes both alendronate and metformin falls under this recommendation. Checking B12 at the same visit as the annual DEXA or bone-marker review is a practical way to integrate this into osteoporosis follow-up care.

Peripheral neuropathy in a patient on alendronate plus metformin should not be attributed to "diabetic neuropathy" until B12 deficiency has been excluded. One study published in Diabetes Care (N=1,111) found that 22% of metformin-using diabetic patients with peripheral neuropathy had serum B12 below 150 pmol/L [15].

Special Populations

Older Adults Over 70

Adults over 70 have both higher fracture risk (justifying bisphosphonate therapy) and higher B12 deficiency prevalence (due to atrophic gastritis and reduced dietary intake). The Institute of Medicine's Dietary Reference Intakes recommend that adults over 50 get most of their B12 from supplements or fortified foods, given the reduced efficiency of food-bound B12 absorption with age [2]. For this population, B12 supplementation alongside alendronate is common, safe, and often beneficial independent of any interaction question.

Patients Post Bariatric Surgery

Bariatric surgery patients have B12 malabsorption due to reduced intrinsic factor production and gastric bypass anatomy. They also have high rates of secondary osteoporosis and may be prescribed bisphosphonates. In this population, parenteral or sublingual B12 is preferred, and oral alendronate may be less appropriate than intravenous zoledronic acid due to GI motility changes. This is a specialist-managed scenario, but the principle is the same: no direct interaction between B12 and the bisphosphonate, but careful attention to B12 status is essential.

Vegetarians and Vegans

Dietary B12 is found almost exclusively in animal products. Vegan patients on alendronate for osteoporosis should be supplementing B12 routinely regardless of drug therapy. Serum B12 below 200 pg/mL is common in strict vegans not supplementing. There is no interaction with alendronate, but the deficiency risk is independent and clinically important.